Actinium Advances ATNM-400 to Higher Dose in Phase 1 Prostate Cancer Trial

• Actinium Pharmaceuticals reported favorable initial safety results from its first-in-human Phase 1 ATNM-400 trial in metastatic castration-resistant prostate cancer.
• Results were presented October 19 at EANM 2026 in Vienna.
• The initial three-patient cohort had no dose-limiting toxicities, dry mouth or severe blood-related adverse events.
• HER3-targeted imaging showed sustained tumor uptake, supporting further evaluation of the radiotherapy beyond PSMA-directed treatments.
• Dose escalation advanced to the second level; the study aims to establish a recommended Phase 2 dose.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY75980) on October 20, 2026, and is solely responsible for the information contained therein.